Claims for Patent: 7,192,936

Summary for Patent: 7,192,936

Title:	Modified 2\' and 3\'-nucleoside prodrugs for treating Flaviviridae infections
Abstract:	2\' and/or 3\' prodrugs of 1\', 2\', 3\' or 4\'-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.
Inventor(s):	LaColla; Paola (Cagliari, IT), Storer; Richard (Folkstone, GB), Gosselin; Gilles (Monpellier, FR), Sommadossi; Jean-Pierre (Cambridge, MA)
Assignee:	Idenix Pharmaceuticals, Inc. (Cambridge, MA) Centre National de la Recherche Scientifique (Paris, FR) Universita Degli Studi Di Cagliari (Cagliari, IT)
Application Number:	11/005,473
Patent Claims:	1. A method for the treatment of a host infected with a Flaviviridae virus, comprising administering an effective treatment amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the formula ##STR00115## or a pharmaceutically acceptable salt thereof, wherein: R.sup.1 is H; mono, di or triphosphate; acyl; an amino acid ester; a carbohydrate; a peptide; or a pharmaceutically acceptable leaving group which when administered in vivo provides a compound wherein R.sup.1 is H or phosphate; R.sup.2 is hydrogen, acyl; an amino acid ester; a carbohydrate; a peptide; or a pharmaceutically acceptable leaving group which when administered in vivo provides a compound wherein R.sup.2 is H; Y.sup.1 is OH, OR.sup.4, NH.sub.2, NHR.sup.4, NR.sup.4R.sup.5; X.sup.1 is a H, CH.sub.3 or fluoro; and each R.sup.4 and R.sup.5 is independently hydrogen, acyl, alkyl, lower alkyl alkenyl, alkynyl or cycloalkyl. 2. The method of claim 1, wherein the virus is hepatitis C. 3. The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof, is administered in combination or alteration with a second anti-viral agent. 4. The method of claim 3, wherein the second anti-viral agent is selected from the group consisting of an interferon, a ribavirin, a nucleoside analog, and a nucleotide polymerase inhibitor. 5. The method of claim 4, wherein the second anti-viral agent is an interferon. 6. The method of claim 5, wherein the second anti-viral agent is selected from the group consisting of pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta and interferon gamma-1b. 7. The method of claim 1 or 2, wherein the compound or pharmaceutically acceptable salt thereof, is in the form of a dosage unit. 8. The method of claim 7 wherein the dosage unit is a tablet or capsule. 9. The method of claim 1, wherein the host is a human. 10. The method of claim 1, wherein the compound is at least 85% by weight of the .beta.-D-isomer. 11. The method of claim 1, wherein the compound is at least 90% by weight of the .beta.-D-isomer. 12. The method of claim 1, wherein the compound or a pharmaceutically acceptable salt thereof is administered in a composition comprising a pharmaceutically acceptable carrier. 13. The method of claim 12, comprising administering an effective amount of the compound or a pharmaceutically acceptable salt thereof, for the treatment of a host infected with a Flaviviridae virus. 14. The method of claim 12, wherein the composition is in the form of a dosage unit. 15. The method of claim 14, wherein said dosage unit contains 50 to 1000 mg of the compound. 16. The method of claim 14, wherein said dosage unit is a tablet or capsule. 17. The method of claim 12, further comprising administering a second anti-viral agent. 18. The method of claim 12, wherein the compound or pharmaceutically acceptable salt thereof, is at least 85% by weight of the .beta.-D-isomer. 19. The method of claim 12 wherein the pharmaceutically acceptable carrier is suitable for oral, parenteral, inhalant or intravenous delivery. 20. The method of claim 1 wherein Y.sup.1 is OR.sup.4 or NNR.sup.4R.sup.5. 21. The method of claim 20, wherein Y.sup.1 is NH.sub.2. 22. The method of claim 20, wherein Y.sup.1 is OH. 23. The method of claim 1 wherein X.sup.1 is H. 24. The method of claim 1, wherein X.sup.1 is fluoro. 25. The method of claim 1, wherein X.sup.1 is CH.sub.3. 26. The method of claim 1 wherein R.sup.2 is acyl. 27. The method of claim 1 wherein R.sup.2 is an amino acid ester. 28. The method of claim 1 wherein R.sup.2 is a peptide. 29. The method of claim 1 wherein R.sup.2 is a carbohydrate. 30. The method of claim 1 wherein R.sup.1 is mono, di or triphosphate. 31. The method of claim 1 wherein R.sup.1 is hydrogen. 32. The method of claim 26, wherein acyl is of the formula C(O)R', wherein R' is a straight, branched, or cyclic alkyl. 33. The method of claim 26, wherein acyl is of the formula C(O)R', wherein R' is aryl, alkaryl, aralkyl alkoxyalkyl or aryloxyalkyl. 34. The method of claim 26, wherein acyl is of the formula C(O)R' wherein R' is aryl. 35. The method of claim 26, wherein R.sup.2 is acetyl. 36. The method of claim 26, wherein R.sup.2 is propionyl, butyryl, hexanoyl, or 2-propenyl. 37. The method of claim 1, wherein R.sup.2 is an ester of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. 38. The method of claim 1, wherein R.sup.2 is an ester of a naturally occurring or synthetic .alpha., .beta., .gamma., or .delta. amino acid. 39. The method of claim 1, wherein R.sup.2 is an ester of an amino acid in the L configuration. 40. The method of claim 1, wherein R.sup.2 is an ester of valine. 41. The method of claim 37, 38 or 40, wherein host is human. 42. The method of claim 1, wherein: X.sup.1 is H, CH.sub.3 or fluoro Y.sup.1 is OH or NH.sub.2 R.sup.2 is acyl or an amino acid ester, and R.sup.1 is H. 43. The method of claim 42, wherein R.sup.2 is an amino acid ester. 44. The method of claim 42, wherein X.sup.1 is fluoro, and Y.sup.1 is OH. 45. The method of claim 42, wherein X.sup.1 is H, Y.sup.1 is NH.sub.2 and R.sup.2 is an amino acid ester. 46. The method of claim 42, wherein X.sup.1 is CH.sub.3, Y.sup.1 is OH and R.sup.2 is an amino acid ester. 47. The method of claim 42, wherein R.sup.2 is an ester of valine. 48. The method of claim 42, wherein the host is human.

Details for Patent 7,192,936

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2022-06-28
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2022-06-28
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2022-06-28